Skip to main content

Table 1 Description of included studies

From: The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

Study Study characteristics Assessment of study quality
Study design Study duration (months) Interventions N Median follow up (months) Median dose % lost to follow up Q1 Q2 Q3 Q4 Q5 Q6
DASISION [13, 2931] Multicentre, Randomised, Phase III   Dasatinib 100 mga 259 18.0 99 mg 15% Yes No Yes No Yes Yes
Imatinib 400 mga 260 400 mg 19%       
Baccarani et al. [32] Prospective, randomised 12 Imatinib 400 mga 108 26 400 mg   No Yes No Yes Yes No
Imatinib 800 mga 108 26 720 mg        
German CML Study IV [33, 34] Randomised 36 Imatinib 800 ga 338 40 646 mg   Yes No No No No No
Imatinib 400 ga 326 40 400 mg        
ENESTed [12, 3537] Multicentre, Randomised, Phase III 60 Nilotinib 300 mgb 282 18 592 mg 16% Yes No Yes No Yes Yes
Nilotinib 400 mgb 281 18 779 mg 18%       
Imatinib 400 mga 283 18 400 mg 21%       
S0325 Intergroup [38] Open Label, Randomised, Phase II 12 Imatinib 400 mga 127     Yes No No No No No
Dasatinib 100 mga 126          
ISTAHIT [39] Multicentre, Randomised, Phase III 24 Imatinib 400 mga 114 12.75 400 mg   Yes No Yes No Yes Yes
Imatinib 800 mga 113 12.75 767 mg        
Cortes et al. [40] Multicentre, Randomised, Phase III 12 Imatinib 400 mga 157 17   0% No No Yes No Yes Yes
Imatinib 400 mga 319 17   0.6%       
SPIRIT [41] Prospective, Randomised, Phase III 24 Imatinib 400 mga 159 47 400 mg 0% Yes No Yes No Yes Yes
Imatinib 600 mga 160 47 590 mg 0%       
  1. a) SID; b) BID; Q1) Was the method used to randomize patients described and adequate?; Q2) Was the method used for allocation concealment described and adequate?; Q3) Were the detailed inclusion/exclusion criteria described?; Q4) Was the method used to ensure treatment blinding described and adequate?; Q5) Were the patient baseline characteristics described? Q6) Were all analyses carried out using data from the Intention To Treat (ITT) patient group?